Confronto
Lixisenatide vs. Retatrutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
320367-13-3
2381089-83-2
Peso molecolare
4858.5 g/mol
4731.6 g/mol
Emivita
3 h
144 h
Sequenza
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMeccanismo d'azione
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
5
di cui sull'uomo
5
4
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Lixisenatide and Retatrutide?
- Lixisenatide is classified as "Metabolico", while Retatrutide is classified as "Metabolico". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Retatrutide?
- The highest available evidence level is "RCT sull'uomo" for Lixisenatide and "RCT sull'uomo" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Retatrutide in Germany and the United States?
- Germania: Lixisenatide — Su prescrizione, Retatrutide — Non approvato. Stati Uniti: Lixisenatide — Non approvato, Retatrutide — Non approvato. These are factual summaries with source and review date on the individual pages.